Tirzepatide is a novel dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Developed primarily for the treatment of type 2 diabetes and obesity, it mimics the activity of two key incretin hormones to enhance insulin secretion, suppress glucagon, and promote weight loss.

Key Benefits

• Dual-action mechanism: Targets both GLP-1 and GIP receptors for superior glycemic control.

• Weight management: Clinically proven to support significant and sustained weight loss.

• Once-weekly dosing: Long-acting formulation for better patient compliance.

High purity and stability: Manufactured under strict GMP standards with excellent quality assurance.

Applications

• Pharmaceutical research and development

• Active pharmaceutical ingredient (API) supply for diabetes and obesity treatments

• Biomedical studies related to metabolic disorders